Table 2.
Demographic and clinical characteristics for TKI-treated and ICI-treated patients.
| Characteristic | HMU TKI-treated patients (N = 67) | HLM ICI-treated patients (N = 149) | ||||||
|---|---|---|---|---|---|---|---|---|
| All | EGFR-DLS | P | All | EGFR-DLS | P | |||
| High (N = 29) | Low (N = 38) | High (N = 39) | Low (N = 110) | |||||
| Age(y) | 0.016* | 0.77 | ||||||
| Mean ± SD | 60.31 ± 9.36 | 57.31 ± 8.65 | 62.61 ± 9.33 | 65.21 ± 13.01 | 65.95 ± 10.36 | 64.95 ± 13.86 | ||
| Sex, no. (%) | 0.007* | 0.45 | ||||||
| Male | 38 (56.72) | 22 (75.86) | 16 (42.11) | 60 (40.27) | 18 (46.15) | 42 (38.18) | ||
| Female | 29 (43.28) | 7 (24.14) | 22 (57.89) | 89 (59.73) | 21 (53.85) | 68 (61.82) | ||
| TNM stage | 0.26 | 0.15 | ||||||
| I | 15 (22.39) | 9 (31.03) | 6 (15.79) | 0 (0) | 0(0) | 0 (0) | ||
| II | 4 (5.97) | 1 (3.45) | 3 (7.89) | 0 (0) | 0(0) | 0 (0) | ||
| III | 15 (22.39) | 4 (13.79) | 11 (28.95) | 25 (16.78) | 2 (5.13) | 23 (20.91) | ||
| IV | 33 (49.25) | 15 (51.72) | 18 (47.37) | 124 (83.22) | 37 (94.87) | 87 (79.09) | ||
| Histology (baseline), no. (%) | 0.016* | 0.048* | ||||||
| ADC | 60 (89.55) | 29 (100) | 31 (81.58) | 100 (67.11) | 21 (53.85) | 79 (71.82) | ||
| SCC | 7 (10.45) | 0 (0) | 7 (18.42) | 49 (32.89) | 18 (46.15) | 31 (28.18) | ||
| Smoke, no. (%) | 0.006* | 1.00 | ||||||
| Never | 40 (59.7) | 23 (79.31) | 17 (44.74) | 54 (36.24) | 14 (35.9) | 40 (36.36) | ||
| Former | 27 (40.3) | 6 (20.69) | 21 (55.26) | 95 (63.76) | 25 (64.1) | 70 (63.64) | ||
| SUVmax | 0.86 | 0.56 | ||||||
| Mean ± SD | 9.5 ± 6.97 | 8.93 ± 5.55 | 9.93 ± 7.93 | 11.67 ± 7.74 | 10.65 ± 6.22 | 12.04 ± 8.21 | ||
| PD-L1 status, no. (%) | NA | <.001* | ||||||
| ≥50% | NA | 22 (14.77) | 3 (7.69) | 19 (17.27) | ||||
| 1–49% | 19 (12.75) | 8 (20.51) | 11 (10.00) | |||||
| 0% | 34 (22.82) | 15 (38.46) | 19 (17.27) | |||||
| Unknown | 74 (49.66) | 13 (33.33) | 61 (55.45) | |||||
| Follow up | <0.001* | <0.001* | ||||||
|
Progression Rate (%) |
34 (50.75) | 7 (24.14) | 27 (71.05) | 94 (63.09) | 33 (84.62) | 61 (55.45) | ||
| PFS, median, month (IQR) |
6.1 (3, 9.36) |
7.5 (3.38,11.15) |
3.75 (2.03,6.10) |
7.67 (2.76,14.99) |
4.20 (1.77,9.27) |
9.18 (3.67,16.00) |
||
| EGFR-deep learning score (EGFR-DLS) | <0.001* | <0.001* | ||||||
|
Median (IQR) |
0.45 (0.23,0.56) |
0.60 (0.54,0.69) |
0.36 (0.10,0.39) |
0.29 (0.11,0.53) |
0.64 (0.57,0.72) |
0.21 (0.09,0.35) |
||
The comparison of age, EGFR-DLS, and SUVmax between two groups was performed using two-sided Wilcoxon sign-rank test, PFS was compared with two-sided log-rank test, and the rest variables were compared with two-sided Fisher’s test. ADC is short for adenocarcinoma and SCC is short for squamous cell carcinoma.
IQR interquartile range, NA not available.
*p Value <0.05.